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Cancer is a major health problem in the world. Advances made in cancer therapy have improved the survival of patients in certain
types of cancer. However, the overall ﬁve-year survival has not signiﬁcantly improved in the majority of cancer types. Major
challenges encountered in having eﬀective cancer therapy are development of drug resistance by the tumor cells, nonspeciﬁc
cytotoxicity, and inability to aﬀect metastatic tumors by the chemodrugs. Overcoming these challenges requires development
and testing of novel therapies. One attractive cancer therapeutic approach is cancer gene therapy. Several laboratories including
the authors’ laboratory have been investigating nonviral formulations for delivering therapeutic genes as a mode for eﬀective
cancer therapy. In this paper the authors will summarize their experience in the development and testing of a cationic lipid-based
nanocarrierformulationandtheresultsfromtheirpreclinicalstudiesleadingtoaPhaseIclinicaltrialfornonsmallcelllungcancer.
Their nanocarrier formulation containing therapeutic genes such as tumor suppressor genes when administered intravenously
eﬀectively controls metastatic tumor growth. Additional Phase I clinical trials based on the results of their nanocarrier formulation
have been initiated or proposed for treatment of cancer of the breast, ovary, pancreas, and metastatic melanoma, and will be
discussed.
1.Introduction
Cancer is a major health problem in the world. In 2009,
about1,479,350peoplelivingintheUnitedStatesofAmerica
(USA), have been diagnosed with cancer [1]. About half of
these cancer patients will die of the disease. The lifetime risk
of developing cancer is predicted to be 1 in 2 for men and
1in3forwomen[1].Disseminationofscientiﬁcinformation
and cancer awareness have reduced the incidence for certain
cancer types while the incidence for other cancer types
remain unchanged or increased. For example, reduced
incidence of lung cancer in men due to cessation of smoking
has been observed while the lung cancer incidence in women
is increasing. Similarly, ignoring the risks of exposure to
ultraviolet rays and the potential for developing skin cancer
has resulted in steady increase in the incidence of melanoma.
Eﬀective cancer therapies developed in recent years have
improved the survival of patients diagnosed with cancer.
However, the overall ﬁve-year survival rate of cancer patients
remain dismal and is less than 15% at least for solid
tumors of epithelial origin [2]. Factors contributing to the
poor survival rate despite having developed novel therapies
include development of resistance to therapy by cancer cells,
poor drug distribution and accumulation in the tumor, and
nonspeciﬁc cytotoxicity to normal tissues thereby limiting
the drug dosage. Thus, there is a tremendous eﬀort in2 Journal of Drug Delivery
developing new cancer therapeutics that are eﬃcacious and
safe with minimal cytotoxicity to normal tissues. Testing and
demonstrationofsuchnewtherapeuticsinpreclinicalstudies
will ultimately lead to testing in humans as a cancer drug.
One therapeutic approach that has shown promise and
safety is cancer gene therapy [3]. The gene therapy approach
that has exploded and tested widely in the last decade is the
use of tumor suppressor genes (TSG’s). Cell division and
cell growth are tightly controlled processes often regulated
by TSG’s. However, alterations such as mutations, deletions,
and silencing at the DNA, RNA, or protein level of TSG
result in dysregulation of the cell growth and transformation
[4]. Retinoblastoma (Rb) and p53 TSG are classical examples
whose function when lost or altered has been shown to
initiate or contribute to cell transformation [5, 6]. Further-
more, p53 gene mutations are observed in a majority of
human cancers, suggesting it is an important gatekeeper of
thecell.ApartfromRbandp53,severalotherTSGshavebeen
identiﬁed and shown to regulate diverse cellular processes
and loss of their function aﬀects normal cell activity. Based
on these observations, it was hypothesized that restoration
of normal TSG function will inhibit cell proliferation and
growth leading to cell death. Thus TSG-based cancer therapy
was conceived and initiated.
Early studies using viral vectors demonstrated that deliv-
ering TSG’s resulted in tumor inhibition in animal models
[3] (see Table 1). Translating these ﬁndings to the clinic
demonstrated clinical and/or biological response to therapy.
Stabilization of the disease (SD) was frequently observed
in patients receiving therapy, and in few cases complete
response to therapy as evidenced by tumors’ regression
[7–10]. Despite the encouraging clinical results observed
in virus-based cancer gene therapy studies, this treatment
strategy has limited application due to the elicitation of host-
immune response by viral proteins [11–14]. Additionally,
testing of virus-based cancer gene therapy for treatment for
metastatic disease has not been proven to be successful so far.
To overcome the limitations encountered with virus-
based cancer therapy, several laboratories including our own
laboratory have been testing nonviral-gene-delivery vehicles
for cancer gene therapy. The nonviral vectors are of diﬀerent
composition and formulations. They also vary in their size
and geometry. A majority of these nonviral vectors are
nanometer (nm) in size and often have a lipid component.
According to the National Cancer Institute (NCI), any
biological or synthetic material which in any one dimension
is less than 1 micrometer (µm) is called a nanoparticle.
Based on this deﬁnition, several nonviral vectors that are less
than 1µm in size are referred as nanoparticles, nanocarriers,
nanosomes, and so forth.
An advantage of using nanoparticles as gene-delivery
vehicles is that they can deliver therapeutic genes to in situ
tumors that are disseminated inside the body [3, 15]. Studies
have demonstrated nanoparticle-based gene-delivery results
in antitumor activity in experimental preclinical tumor
models. An added advantage of using nonviral nanocarrier
systems, apart from the ease of manufacturing, is the avoid-
ance of problems frequently encountered with adenovirus
[15, 16].
Inthispaper,wewilldiscussourexperienceswithalipid-
based nanocarrier that was initially tested in the laboratory
as a tumor suppressor gene-delivery vehicle and later tested
in the clinic for the treatment of nonsmall cell lung cancer
(NSCLC). Plans for applying our nanocarrier-based cancer
gene therapy technology for treatment of other solid cancers
will also be discussed.
2. Gene-BasedNanotherapy
2.1. Laboratory Studies. Our interest in testing lipid-based
nanocarriers as gene-delivery vehicles arises from the fol-
lowing observations: (1) cancer is often metastasized in
patients at the time of their initial diagnosis [1, 2]; (2)
conventional therapies are ineﬀective in treating metastatic
disease [17, 18]; (3) our own laboratory studies demon-
strate that virus-based (retrovirus and adenovirus) tumor
suppressor gene therapy for systemic therapy of metastatic
cancer was ineﬀective; (4) preclinical studies demonstrated
that nonviral vectors can deliver genes and drugs to localized
and disseminated tumors [19–21].
Although several lipid-based nanocarriers were reported
in the literature to be eﬃcient gene-delivery vehicles, most
of these studies were restricted to in vitro testing with
few being tested in vivo [22–27]. Furthermore, only a
limited number of nanocarriers has moved beyond the
laboratory and has been tested in the clinic (see Table 2).
The reasons for their inability to test several nanocarriers in
the clinic are multifactorial and include inability to produce
clinical grade nanocarriers in large quantities, inﬂammatory
response [28–30], poor stability and short half-life of the
nanocarrier in vivo [31, 32], interaction with serum proteins
and aggregation [33, 34], poor uptake of the nanocarrier
by the tumors, and rapid clearance by macrophage and the
reticuloendothelial system (RES) [35].
Methods to overcome some of these limitations included
PEGylation of the nanocarriers using polyethylene gly-
col (PEG). Pegylated nanocarriers demonstrated improved
stability in vivo, reduced RES clearance, and increased
accumulation in tumors resulting in enhanced antitumor
activity[36–38].Similarly,studiesusingneutralornegatively
charged nanocarriers have reported eﬀective delivery of
oligonucleotides, siRNA, and chemotherapeutic drugs [39,
40]. Despite the advances made with neutral and anionic
lipid-based nanocarriers, they have not been developed and
tested widely as tumor-suppressor gene-delivery vehicles for
cancer therapy.
In 1998, Templeton et al. [41] reported that cationic
DOTAP:cholesterol (DOTAP:Chol) lipid nanocarrier eﬃ-
ciently delivered plasmid DNA to the lung when admin-
istered intravenously. Findings by Gaensler et al. [42]
concurred that DOTAP:Chol lipid nanocarrier to be an
eﬃcient gene-delivery vehicle. Crook et al. [43] reported that
inclusionofcholesterolwasimportantandakeytoachieving
stabilization of the DOTAP:Chol-nanocarrier and eﬃcient
gene transfer. The key feature that makes this nanocarrier
better than previously tested lipid-based nanocarriers is its
stability and reduced interaction with blood proteins in vivoJournal of Drug Delivery 3
Table 1: Tumor suppressor genes tested as cancer therapeutic in preclinical studies.
TSG Cancer Animal model Therapeutic outcomes Molecular events
E1A Ovarian Intraperitoneal
tumor
Reduced abdominal tumor
burden; increased animal
survival
Apoptosis, reduced
ascites, and cell cycle
arrest
p53 Lung
Subcutaneous
tumor; experimental
lung metastasis
Tumor-growth inhibition;
reduced extrapulmonary
tumor nodules and increased
animal survival
Cell cycle arrest,
apoptosis,
andantiangiogenesis
Fhit Lung
Subcutaneous
tumor; experimental
lung metastasis
Tumor-growth inhibition;
reduced extrapulmonary
tumor nodules and increased
animal survival
Cell cycle arrest and
apoptosis
IL-24 Lung
Subcutaneous
tumor; experimental
lung metastasis
Tumor-growth inhibition;
reduced extrapulmonary
tumor nodules; increased
animal survival
Cell cycle arrest,
apoptosis,
antiangiogenesis, and
autophagy proimmune
activity
Fus1 Lung
Subcutaneous
tumor; experimental
lung metastasis
Tumor-growth inhibition;
reduced extrapulmonary
tumor nodules; increased
animal survival
Cell cycle arrest and
apoptosis
BiKDD Pancreas
Subcutaneous
tumor; orthotopic
tumor
Tumor-growth inhibition;
reduced metastasis, increased
animal survival
Apoptosis
which is contributed by the inclusion of cholesterol [41].
Another key feature that likely contributes to its eﬀectiveness
is that the lipid-nanocarrier, when mixed with DNA, forms
unique bilamellar vase-like structures that keep the DNA
intact from rapid degradation [41]. However, it is likely that
additional factors that are unknown at the present time may
contribute to its eﬀectiveness.
Based on these reports, we initiated preclinical studies
in our laboratory and tested whether DOTAP:Chol-lipid
nanocarrier could eﬃciently deliver tumor suppressor genes
when administered systemically and control metastatic lung
tumors. Size fractionation studies showed our lipid nanocar-
rier was 200–400nm in size and had a positive charge of
40 ±2mV[44,45].Thenanocarriersarestable+4◦Cforover
a period of one month when stored as empty nanocarriers
and for at least 48h when mixed with DNA. Although one
may argue that our nanocarriers are large, results from our
studies, as discussed below, support particle size of 200–
400nm to be optimal and to strike a balance between tumor
uptake and macrophage clearance. Furthermore, we believe
that the size of the nanocarrier will need to be varied and
optimized depending on the disease to be treated and that
the concept of one-size-ﬁts-all disease treatments cannot be
applied.
In vitro studies showed transfection eﬃciency mediated
by the nanocarrier varied among cell types that correlated
with transgene expression [44, 46, 47]. Transgene expres-
s i o nw a so b s e r v e dt ob ed e t e c t a b l ea se a r l ya s1 2 ha f t e r
transfection and was detectable up to 72h after transfection
albeit expression levels decreased over time. The transfection
eﬃciency and transgene expression were observed to be
consistent in a given cell line even when diﬀerent tumor
suppressor genes or marker genes were used. One factor that
aﬀected transfection eﬃciency and transgene expression was
the size of plasmid contained in the nanocarrier. In general,
a nanocarrier containing a plasmid that was 3-4Kb in
size produced higher transfection compared to nanocarrier
containing a plasmid that was greater than 4Kb in size.
Furthermore,theDNA-containingnanocarrierwasstablefor
at least 48h when stored at +4◦C and produced comparable
transfection eﬃciency and transgene expression in tumor
cells when compared to that produced by cells treated with
a freshly prepared DNA-containing nanocarrier.
In vivo studies were initially focused on biodistribution
and toxicity of the DNA-containing nanocarrier in immuno-
competent mice. Biodistribution studies showed that the
DNA-nanocarrier primarily localized to the lung when
injected intravenously. However, over time the nanocarrier
exited the lung and was detectable in other organs (liver,
spleen, kidney etc). Toxicity studies demonstrated a dose-
dependent response with LD10 being in the range of 55–
70µg of DNA in the lipid nanocarrier and depended on
the backbone of the plasmid DNA. The therapeutic gene
contributed very little to toxicity (unpublished data).
We next investigated the therapeutic eﬀects of a TSG-
containing nanocarrier on human lung tumor xenografts
established in nude mice. Marker gene expression showed
marked transgene expression when injected intratumorally
intosubcutaneouslungtumorxenografts[40].Eﬃcacystud-
ies showed that a TSGs-containing (p53, Fhit, Fus1, TSG101,
or IL-24) nanocarrier, when administered intratumorally,
produced signiﬁcant growth inhibition compared to tumor
growth inhibition produced by nanocarrier treatment con-
tainingcontrolplasmidDNA[44,46,47].Growthinhibition,4 Journal of Drug Delivery
Table 2: Synthetic nanocarriers tested for cancer gene therapy in human Phase I clinical trials.
Nanocarrier Therapeutic
gene Cancer Route of administration
DC (3 beta-[n-(N ,N  -dimethylaminoethane)-
carbamoyl]cholesterol): DOPE
(dioleoylphosphatidylethanolamine)
E1A Breast/ovarian Intratumoral (it)/intraperitoneal (ip)
DC (3 beta-[n-(N ,N  -dimethylaminoethane)-
carbamoyl]cholesterol): Chol
(cholesterol)
EGFR Head & neck Intratumoral
DOTAP (N-[1-(2, 3-dioleoyloxy)propyl]-
N,N,N-trimethylammonium Chloride): DOPE
(dioleoylphosphatidylethanolamine)
p53 Solid tumor Intravenous (iv)
DOTAP (N-[1-(2, 3-dioleoyloxy)propyl]-
N,N,N-trimethylammonium Chloride): Chol
(cholesterol)
BiKDD Pancreatic
cancer Intravenous (iv)
DOTAP (N-[1-(2, 3-dioleoyloxy)propyl]-
N,N,N-trimethylammonium Chloride): Chol
(cholesterol)
E1A Breast/ovarian Intravenous (iv)
DOTAP (N-[1-(2, 3-dioleoyloxy)propyl]-
N,N,N-trimethylammonium Chloride): Chol
(cholesterol)
Fus1 Lung Intravenous (iv)
DOTMA (N-[1-(2,3-dioleyloxy)propyl]-
N,N,N-trimethylammonium Chloride): Chol
(cholesterol)
IL-2 Head & neck Intratumoral (it)
Source: www.cancertrials.gov.
produced by TSG-containing nanocarrier was independent
of the tumor model, as comparable growth-inhibitory eﬀects
were observed in human H1299 lung tumor and murine
UV2237tumorxenograftsestablishedinnudemiceandC3H
mice, respectively [46]. Furthermore, repeated treatments
showedgreatertumor-growthinhibitionthatcorrelatedwith
increased transgene expression when compared to growth-
inhibitory eﬀects produced by single treatments. Our study
alsoshowedthatthetherapeuticeﬀectproducedbyp53TSG-
containing nanocarrier treatment was independent of the
endogenous p53 status of the treated tumor. Additionally,
the therapeutic eﬀect produced using various TSGs was
comparable, albeit diﬀerences existed among tumor types.
These results provide evidence and support intratumoral
treatmentsoflocalizedtumorssuchascanceroftheheadand
neck that are unresectable with TSG-containing nanocarrier.
It is envisioned that such localized intratumoral treatments
with TSG-containing nanocarrier will reduce the tumor
burden and make the tumor accessible to surgery and
radiation therapy.
Sinceourobjectiveandgoalwastotestthenanocarrieras
a systemic gene-delivery vehicle for treatment of metastatic
disease, we conducted in vivo studies using experimental
tumor-metastasis models. Human H1299 (p53 null) and
A549(p53wild-type)tumorcellswereinjectedintravenously
via tail vein to establish experimental lung metastasis in
SCID/Beige and nude mice, respectively. Mice received
daily intravenous treatments with a p53 TSG-containing
nanocarrier for a total of six doses. At four weeks after the
last treatment mice were euthanized, lungs were harvested
and examined for the number of pulmonary nodules.
A signiﬁcant reduction in the number of pulmonary tumor
nodules were observed in mice receiving p53 TSG nanocar-
rier treatment compared to the number of pulmonary tumor
nodules in mice receiving control DNA-containing nanocar-
rier treatment [44]. Histopathological examination of the
lungs from mice receiving p53 TSG-containing nanocarrier
treatment showed few tumors with evidence of tumor cells
undergoing apoptotic cell death compared to the number of
tumors in the lungs of control mice and very few tumor cells
undergoing apoptosis.
Since the six-day treatment with p53 TSG-containing
nanocarrier did not completely abolish pulmonary tumor
growth we next determined whether these tumors will
regrow and if they can be treated with a second cycle
of treatment akin to that practiced in the clinic. For
this purpose, mice bearing experimental lung tumors were
divided into two groups. One group of mice (n = 8) received
the initial six treatments with p53 TSG nanocarrier (day 1–
6). A second group of mice (n = 8) received the initial six
treatmentswithp53TSGnanocarrier(day1–6)andasecond
cycle of six treatments starting on day 30 (day 30–35). Mice
(n = 4) from each group were euthanized on day 28 and
on day 42. Lungs were harvested from the euthanized mice
and the number of lung tumor nodules counted. Our results
showed that a greater reduction in the number of pulmonary
tumor nodules in the lungs of mice receiving two cycles of
p53 TSG nanocarrier treatment compared to the reduction
in tumor nodules in the lungs of mice receiving single cycle
of p53 TSG nanocarrier treatment (unpublished data). Our
results demonstrate repeated cycles of treatment are feasible
and that they produced a greater therapeutic eﬀect.Journal of Drug Delivery 5
We next determined the therapeutic eﬀects of p53 TSG-
containingnanocarrierindisseminatedtumormousemodel.
Injection of H1299 lung tumor cells into SCID/Beige mice
results in disseminated tumors in various organs [44]. Treat-
ing these mice with the p53 TSG nanocarrier intravenously
resulted in prolonged animal survival compared to survival
of control mice that were either untreated or treated with a
control plasmid DNA-containing nanocarrier [44].
Eﬀective gene-delivery mediated by the nanocarrier was
not restricted to p53 TSG therapy or to lung tumor models.
Delivery of Fhit and Fus1 TSGs, that are frequently lost in
human lung cancer, produced therapeutic eﬀects that were
similar to the therapeutic eﬀects observed with p53 [44, 47].
Furthermore, combination of Fus1-containing nanocarrier
with chemotherapy was shown to produce additive to
synergistictherapeuticeﬀect[48].Similarly,systemictherapy
with IL-24-containing nanocarrier inhibited human lung
tumor and murine ﬁbrosarcoma growth established in nude
mice and immunocompetent C3H mice, respectively [46].
In all of these studies repeated treatments resulted in
additive increases in transgene expression in the tumors
with minimal expression in normal tissues adjacent to the
tumor [49], a ﬁnding that was in contrast to the report
by Li et al. [50] who showed repeated treatments reduced
transgene expression due to induction of treatment-related
inﬂammatory response. The diﬀerences in the outcomes
were due to diﬀerence in the animal models used. We
demonstrated that mice bearing tumors produced immuno-
suppressive factors within the tumor microenvironment
that altered the host immune pathology resulting in no
inhibitory eﬀects on transgene expression [51]. Additionally,
nanocarrier tracking studies demonstrated tumors that were
larger in size had more nanocarriers compared to tumors
that were smaller in size [49]. The uptake of the nanocarriers
involved tumor-mediated phagocytosis. Furthermore, the
inﬂammatory response produced in the tumor-bearing mice
was markedly reduced. On the contrary, if the mice did not
bear any tumors then the nanocarrier was widely distributed
in the lung, and induction of treatment-related inﬂamma-
tory response and shutting down of transgene expression
following repeated treatments was observed [44, 49, 52].
Thus, the outcomes of repeated nanocarrier treatment and
transgene expression can be regulated by the host pathology
and disease conditions and therefore need to be considered
during drug development.
More recently, we have tested the systemic therapeu-
tic eﬀects of IL-24-containing nanocarrier treatments in
a metastatic melanoma model. Nude mice injected with
human melanoma (MeWo) tumor cells that are genetically
modiﬁed to express the green ﬂuorescent protein (GFP)
produced tumors that metastasized to the lung, liver, brain,
and several other organs and visible under bright light
and ﬂuorescent light (Figure 1). Mice injected with MeWo-
GFP cells and bearing experimental metastasis were divided
into the following groups: no treatment; treatment with
IL-24 plasmid DNA; treatment with empty nanocarrier;
treatment with IL-24-containing nanocarrier. Mice were
treated twice a week (50µg DNA) until the study was
terminated. Treatment of these mice having experimental
metastasis intravenously with IL-24-nanocarriers resulted in
prolonged animal survival compared to survival of mice that
r e c e i v e do t h e rt r e a t m e n t so rn ot r e a t m e n t( F i g u r e2). These
studies showed systemic treatment with our nanocarrier
delivers therapeutic genes and produces eﬀective anticancer
activity.
We next determined whether our nanocarrier can deliver
TSGs to ovarian cancer when administered intraperitoneally
(i.p.) and whether it was superior to adenovirus-mediated
gene-delivery in producing a therapeutic eﬀect. Nude mice
were injected into the peritoneum with human ovarian
MDAH2774 tumor cells. The mice rapidly form ascites with
disease progression and at which time if untreated they
will have to be euthanized. These i.p. tumor-bearing mice
were divided into groups and treated as follows: treated
with IL-24-containing nanocarrier, treated with adenovirus
(Ad)-IL-24, treated with Ad-luciferase (Luc), or treated with
phosphate buﬀered saline (PBS). Animals were monitored
daily and animal survival recorded. As shown in Figure 3,
mice receiving IL-24-containing nanocarrier showed a trend
for increased survival compared to all other treatment
groups. Our preliminary results showed nanocarrier-based
therapy was more eﬀective than adenovirus-based therapy
in controlling tumor growth and progression for ovarian
cancer. Finally, our studies demonstrate DOTAP:Chol-based
nanocarrier is eﬃcient in delivering therapeutics genes to
local and metastatic tumor sites and can be administered via
various routes resulting in enhanced therapeutic eﬀects in
preclinical models.
2.2. Clinical Studies. On the basis of our preclinical studies,
a Phase I clinical trial for the systemic treatment of nonsmall
cell lung cancer (NSCLC) has been initiated at the University
of Texas MD Anderson Cancer Center, Houston, Texas,
USA [53]. This trial which is a ﬁrst of its kind aims
at testing whether DOTAP:Chol. nanocarrier-containing a
TSG, Fus1, can be administered intravenously in patients
withrecurrent/metastaticlungcancerpreviouslytreatedwith
platinum-based chemotherapy. Fus1 is a TSG located on
chromosome 3p21.3 [54, 55]. The rationale for selecting
Fus1 for NSCLC therapy is because it is frequently lost
or deleted in more than 60% of patients diagnosed with
lung cancer [56]. Additionally, studies have shown that Fus1
eﬀectively suppressed lung-tumor growth in vivo when used
asmonotherapyorincombinationwithotherdrugs[57–59].
The primary objective of this trial is to treat patients with
an escalating dose (0.01–0.09mg/Kg) of Fus1-containing
nanocarrier at a three-week interval and determine the
maximum tolerated dose (MTD). Up to date, 23 patients
have been entered on the study trial and have received one
ormoreFus1-containingnanocarriertreatment.Preliminary
results demonstrate Fus1 nanocarrier treatment is well
tolerated with no major treatment-related toxicity [53].
Furthermore, MTD is yet to be determined, and the trial is
open and continuing to accrue patients. The ﬁnal results of
the Fus1 nanocarrier treatment is expected to be available
upon completion of the trial. The outcome of this trial will
facilitate the design of future TSG-nanocarrier-based Phase
I/II clinical trials for lung cancer.6 Journal of Drug Delivery
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Figure 1: Detection of melanoma metastasis by ﬂuorescent imaging. Human melanoma MeWo cell line was stably transfected and selected
for GFP positive clones. The MeWo-GFP cells (5 × 106) were injected intravenously via tail vein in nude mice. Mice were euthanized after
four to ﬁve weeks and observed under normal white light and under ﬂuorescent light. Melanoma tumors were detectable under white light
in various organs. However, an increased number of GFP-positive tumors (green ﬂuorescence) were observed under ﬂuorescence light in
various organs indicating melanoma metastasis. Additionally, tumors not visible under white light were detected by ﬂuorescence.Journal of Drug Delivery 7
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Figure 2: IL-24 nanotherapy improves animal survival. Nude mice
were injected with MeWo-GFP. Ten days after tumor cell injection
mice were divided into four groups: group received no treatment;
group 2 received IL-24 plasmid DNA; group 3 received empty
nanocarrier; group 4 received IL-24-containing nanocarrier (50µg
DNA). Treatment was twice a week and administered intravenously
for six weeks. Mice were monitored for animal survival. Mice
receiving IL-24-containing nanocarrier therapy showed increased
survival compared to all other treatment groups.
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Figure 3: IL-24 nanotherapy for ovarian cancer. MDAH2774 (1 ×
106)cellswereinjectedintotheperitonealcavityofnudemice.Mice
were then divided into groups and treated with IL-24-containing
nanocarrier intraperitoneally (i.p.). Mice that were treated with
phosphate buﬀered saline (PBS), treated with adenovirus (Ad)-
IL-24, or treated with Ad-luciferase (Luc) served as controls. An
increase in animal survival was observed in mice that received IL-
24-containingnanotherapycomparedtoallothertreatmentgroups.
On the basis of our preclinical studies and the Fus1-
containing nanocarrier Phase I clinical trial, two additional
Phase I clinical trials for the treatment of pancreatic cancer,
ovarian, and breast cancer have been approved by the Food
and Drug Administration (FDA) (see Table 2). These trials
will be conducted at the MD Anderson Cancer Center,
Houston, TX, USA. Both of these trials have objectives and
endpoints similar to the Fus1 trial. The only diﬀerence is
the therapeutic gene to be used for these cancer types is
diﬀerent and not Fus1. For pancreatic cancer, a proapoptotic
gene called Bcl-2 interacting killer (Bik) gene (BikDD) will
be used for therapy [60]. The uniqueness is that BikDD
gene expression will be under the control of cholecystokinin
typeAreceptor(CCKAR)thatwillbeconditionallyregulated
byVP16-GAL4-WPRE integrated systemic ampliﬁer(VISA).
This system is tumor selective and high BikDD protein
expression is expected to occur in cancer cells with minimal
protein expression occurring in surrounding normal tissues,
and thus eliminating unwanted cytotoxicity. The objective of
the pancreatic cancer Phase I clinical trial is to determine the
MTD and optimal biological active dose (OBAD) compared
with the clinical response. The trial has not been completed,
and the results from this trial are therefore pending.
In the Phase I clinical trial planned for breast cancer
treatment, the therapeutic gene to be incorporated into the
DOTAP:Chol.nanocarrieristheE1Atumorsuppressorgene.
E1A gene introduction into breast cancer cells induces cell
c y c l ea r r e s ta n dc e l ld e a t hb o t hin vitro and in vivo [61].
Additionally, E1A has previously been tested in a Phase
I clinical trial for treatment of breast and ovarian cancer
patients. Although results from the early trial did not show
any therapeutic beneﬁts, it demonstrated E1A treatment was
safe [62]. This trial, like the pancreatic trial, is currently open
for patient accrual and not completed. Therefore, results
from this trial will remain unknown for, at least, the next one
to two years.
More recently plans for a Phase I clinical trial testing
systemic IL-24 nanocarrier therapy for metastatic melanoma
is underway. Preclinical eﬃcacy and toxicity studies, that are
prerequisites for submitting IL-24 nanocarrier as investiga-
tional new drug (IND), have been completed. The IL-24
nanocarrier phase I clinical trial is yet to receive approval
from the Food and Drug Administration (FDA) and will be
conductedattheMDAndersonCancerCenter,Houston,TX,
USA.
ItisevidentfromthenumberofPhaseIclinicaltrialsthat
have been initiated on the basis of our laboratory ﬁndings
that the lipid-based DOTAP:Chol nanocarrier is useful for
systemic delivery of cancer gene therapeutics. Successful
translation of laboratory research to a clinic such as ours
described above will lead to promising cancer treatment
strategies and therapies. It is anticipated that additional
laboratory research will be translated to the clinic in the next
few years.
3. Conclusions
Since the inception and testing of gene-based therapies
for cancer in the early 1990s, signiﬁcant progress in the
understanding of the biology of the disease and vector
development has been made. Failure to control and/or8 Journal of Drug Delivery
eradicate cancer using virus-based cancer gene therapy has
led to advancement of the nonviral delivery ﬁeld. Despite
skepticism and unexpected gene therapy related deaths,
progress has been made in the area of cancer gene therapy
and will continue to be made. It is evident from the
progress made in our own laboratory, by moving laboratory
research to the clinic one could successfully translate future
research for cancer therapy. Since combination therapies
have often been reported to produce additive to synergistic
therapeutic eﬀect, it is not far from testing Fus1 nanocarrier
incombinationwithconventionalchemotherapiesormolec-
ularly targeted therapies. For example one could combine
Fus1 nanocarrier with the epidermal growth factor receptor
(EGFR) kinase-targeted inhibitors for treatment of lung
cancer. Similarly, IL-24 nanocarrier therapy can be com-
bined with Raf-targeted inhibitor (sorafenib) or alternatively
with the chemotherapeutic Temozolomide for treatment
of metastatic melanoma. Given the possibility of testing
various combinations, it is critical that the ongoing Phase
I clinical trials are successful so that future clinical trials
incorporating combination therapies can be designed and
tested.
With the advent of nanotechnology and its application
tocancermedicine,novelnonviralvector-basednanocarriers
that are multifunctional in their properties have been devel-
oped and are currently being tested in several laboratories
around the world [24, 63–65]. It is thus not far from the
near future that several Phase I clinical trials based on novel
nanoformulations and properties will be initiated for testing
drugs, genes, siRNA, aptamers, or molecular imaging agents
for cancer diagnosis and therapy [27, 66, 67].
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